|
| Press Releases |
|
 |
|
| Friday, September 4, 2020 |
|
|
Avance Clinical Client Immunic, Inc. Announced Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function |
| The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical is pleased to share the news that its client Immunic Therapeutics has announced dosing of the first healthy volunteer in the company's phase 1 clinical program of IMU-856, an novel treatment for patients suffering from gastrointestinal diseases, including diarrhea-predominant irritable bowel syndrome, ulcerative colitis and Crohn's disease. more info >> |
|
| Thursday, July 23, 2020 |
|
|
아방스 클리니컬, 아토사 테라퓨틱스의 두 번째 코로나19 치료제 개발 프로그램인 비강 분무용 치료제 AT-301 임상 연구 계약 |
| 호주의 앞서가는 바이오텍 임상시험수탁기관(CRO)이자 프로스트 앤 설리번(Frost & Sullivan)이 ‘2020 아시아 태평양 CRO 시장 선두기관’으로 선정한 아방스 클리니컬(Avance Clinical)은 아토사 테라퓨틱스(Atossa Therapeutics)의 비강 분무용 전매 신약 후보인 AT-301 관련 임상 연구 시행 계약을 맺었다. 아방스 클리니컬은 아토사 테라퓨틱스의 전매 약제인 엔독시펜(Endoxifen) 임상 연구를 몇 차례 성공적으로 완료한 바 있다. more info >> |
|
|
Avance Clinical簽約展開Atossa Therapeutics AT-301鼻噴霧劑臨床研究，這是Atossa的第二個新冠肺炎治療開發項目 |
| 澳大利亞領先的生物技術CRO和Frost & Sullivan 2020年亞太區CRO市場領導獎獲得者Avance Clinical正式簽約，對Atossa Therapeutics的專利候選藥物AT-301進行臨床研究，該藥物將通過鼻噴霧劑給藥。 Avance已經成功地完成了Atossa專利Endoxifen的多項臨床研究。 more info >> |
|
|
Avance Clinical签约展开Atossa Therapeutics AT-301鼻喷雾剂临床研究，这是Atossa的第二个新冠肺炎治疗开发项目 |
| 澳大利亚领先的生物技术CRO和Frost & Sullivan 2020年亚太区CRO市场领导奖获得者Avance Clinical正式签约，对Atossa Therapeutics的专利候选药物AT-301进行临床研究，该药物将通过鼻喷雾剂给药。Avance已经成功地完成了Atossa专利Endoxifen的多项临床研究。 more info >> |
|
| Wednesday, July 22, 2020 |
|
|
Avance Clinical Contracted for Atossa Therapeutics AT-301 Nasal Spray Clinical Study, Atossa's Second COVID-19 Therapeutic Development Program |
| The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical has been contracted to conduct a clinical study of Atossa Therapeutics' proprietary drug candidate AT-301, to be administered by nasal spray. Avance has successfully completed multiple clinical studies of Atossa's proprietary Endoxifen. more info >> |
|
| Thursday, July 9, 2020 |
|
|
아방스 클리니컬, 프로스트 앤 설리번의 “2020 아시아태평양 CRO 시장 리더십 어워즈” 수상 |
| 호주 바이오테크 분야 임상시험수탁기관(CRO) 중 선두를 달리고 있는 아방스 클리니컬(Avance Clinical)은 지난 밤 프로스트 앤 설리번 (Frost & Sullivan) 주체로 열린 2020 아시아태평양 CRO 시장 리더십 어워즈 온라인 시상식에서 수상했다. more info >> |
|
|
Avance Clinical榮獲Frost & Sullivan 2020亞太CRO市場領導力獎 |
| Avance Clinical在全球遠程線上獎頒獎典禮上榮獲由Frost & Sullivan 頒發的久負盛名的 2020亞太CRO市場領導力獎，其是澳大利亞在CRO 生物技術方面領先的公司。 more info >> |
|
|
Avance Clinical荣获Frost & Sullivan“2020亚太CRO市场领导力奖” |
| Avance Clinical在全球远程线上奖颁奖典礼上荣获由Frost & Sullivan 颁发的久负盛名的“2020亚太CRO市场领导力奖”，其是澳大利亚在CRO 生物技术方面领先的公司。 more info >> |
|
|
Avance Clinical Wins Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award |
| The leading Australian CRO for biotechs, Avance Clinical, accepted the prestigious Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award at a global virtual awards ceremony overnight. more info >> |
|
| Wednesday, June 10, 2020 |
|
|
바이오 디지털2020 참가한 아방스 클리니컬, “트라이얼트로브 데이터 통해 호주의 우호적 기업 환경 드러나” |
| 호주의 앞서가는 임상시험수탁기관(CRO)인 아방스 클리니컬(Avance Clinical)은 오늘 열린 바이오 디지털(BIO Digital) 행사에 참가해 현재 호주에서 계획 중이거나 진행 중인 임상시험 건수가 2,413건에 달한다고 밝혔다. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Kincora Consolidates, Commences Geophysics and Forms Partnership at Cowal East
Mar 10, 2026 17:59 HKT/SGT
|
|
|
Fosun Navigates Cyclical Volatility and Clears Risks as Management Reaffirms RMB10 Bn Profit Target for Next 3 to 5 Yrs
Mar 10, 2026 16:45: JST
|
|
|
Entertainment Expo Hong Kong shines on the centre stage, Eight signature events unite global film and entertainment forces
Mar 10, 2026 16:17 HKT/SGT
|
|
|
Fosun Navigates Cyclical Volatility and Clears Risks as Management Reaffirms RMB10 Bn Profit Target for Next 3 to 5 Yrs
Mar 10, 2026 15:45 HKT/SGT
|
|
|
直面週期波動 復星出清風險 管理層明確未來三至五年百億利潤目標不變
Mar 10, 2026 15:37 HKT/SGT
|
|
|
三菱重工、防衛省向け3,000トン型潜水艦「ちょうげい」の引渡式を神戸造船所にて実施
Mar 10, 2026 15:30: JST
|
|
|
鹰普精密2025年股东应占溢利创新高至726.2百万港元 同比上升12.7% 2026年销售增长加速 预测增长率约为中双位数
Mar 10, 2026 14:40 HKT/SGT
|
|
|
Impro Precision 2025 Profit Attributable to Shareholders Reaches Record High of HK$726.2 Million, Up 12.7% Year-on-Year, Forecast 2026 Sales Growth Rate to Accelerate to Mid-Double Digits
Mar 10, 2026 14:19 HKT/SGT
|
|
|
鷹普精密2025年股東應佔溢利創新高至726.2百萬港元 同比上升12.7% 2026年銷售增長加速 預測增長率約為中雙位數
Mar 10, 2026 14:03 HKT/SGT
|
|
|
Natural Beauty's 2025 Annual Results Show Steady & Robust Growth
Mar 10, 2026 13:35 HKT/SGT
|
|
|
自然美2025年度業績穩健躍升 「AI科美 大健康」戰略驅動轉虧為盈
Mar 10, 2026 13:16 HKT/SGT
|
|
|
51WORLD旗下51Sim以53.5%市佔率穩居中國高階智能駕駛仿真市場第一
Mar 10, 2026 12:44 HKT/SGT
|
|
|
51WORLD旗下51Sim以53.5%市占率稳居中国高阶智能驾驶仿真市场第一
Mar 10, 2026 12:34 HKT/SGT
|
|
|
Xiamen C&D Inc.'s New Five-Year Strategic Plan Released, Aiming to Accelerate Globalization
Mar 10, 2026 12:30 HKT/SGT
|
|
|
Agent first不是口號：LeapCat.ai如何讓AI"嵌入"而非"附著"于金融業務
Mar 10, 2026 11:56 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
